The new drug Zepzelca (lurbinectin) for metastatic small cell lung cancer (SCLC) has been approved
-
Last Update: 2020-06-25
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The pharmaceutical company Jazz said thatFDAapproved Zepzelca (lurbinectin) for the treatment of metastatic small cell lung cancer (SCLC), an alkylification drug that binds to the remains of the bird's radon in DNA and inhibits the transcription of cancer-causing genes in tumor-related macrophagesThe FDA's decision was supported by data on single-drug treatment data from the Single Arm II study, which treated 105 platinum-sensitive and platinum-resistant SCLC patientsThe results of the Phase II study showed that the overall remission rate (ORR) of patients in the Patients with Recurrent SCLC was 35% and the median duration of the remission was 5.3 monthsThe ORRs of platinum-sensitive and platinum-resistant patients were 45% and 22.2%, respectivelyJazz CEO Bruce Cozadd noted that SCLC's current treatment options are limited, so Zepzelca represents an important step forward in the treatment of recurrent diseasesZepzelca will be available in the U.Sin early July, according to JazzSmall cell lung cancer (SCLC) is one of the most malignant types in lung cancer, with fast progress, early metastasis, easy recurrence and so on, accounting for about 15%-20% of new lung cancer, its occurrence and long-term smoking is closely relatedThe median survival of sCLC untreated patients is only 2-4 months
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
